Yara Abdou: Navigating Treatment pathways in Metastatic HR+ Breast cancer

Yara Abdou shared a post on X:

“With the expanding arsenal of endocrine & targeted therapies, treating HR+ HER2- MBC requires seamless integration of clinical, molecular & patient-specific factors to deliver personalized & effective care.

Check out our latest article in Journal of Clinical Oncology on navigating treatment pathways in HR+MBC.”

Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies

Authors: Prarthna V. Bhardwaj and Yara Abdou.

Source: Yara Abdou/X

Yara Abdou, MD, specializes in the treatment of early stage and metastatic breast cancer. Her research focuses on the development of novel therapies, particularly immunotherapy, to treat different subtypes of breast cancer. She works closely with basic and translational scientists to study the breast tumor microenvironment and find ways to enhance treatment approaches by utilizing the immune system. In addition, her research also focuses on racial differences in tumor biology and immune microenvironment, to better understand racial disparities and improve clinical outcomes in minority women with breast cancer. As a clinician and a researcher, her goal is to improve treatment strategies for breast cancer while minimizing suffering and morbidity from the disease.